In vivo magnetic resonance spectroscopy of transgenic mouse models with altered high-energy phosphoryl transfer metabolism

NMR in Biomedicine

Volumn 20, Issue 4, 2007, Pages 448-467

  Renema, W Klaas Jan ^a   Kan, Hermien E ^a   Wieringa, Bé ^a   Heerschap, Arend ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

High energy phosphoryl compound; Metabolism; MR spectroscopy; Transgenic mice

Indexed keywords

BIOMARKERS; ENZYME ACTIVITY; GENES; MAGNETIC RESONANCE SPECTROSCOPY; METABOLISM; METABOLITES; TISSUE;

PHOSPHORYL TRANSFER; VIRAL TRANSDUCTION;

PHOSPHORYLATION;

ADENYLATE KINASE; CREATINE KINASE; GUANIDINOACETATE METHYLTRANSFERASE;

BRAIN; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME SUBSTRATE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENOTOXICITY; HEART; HIGH ENERGY PHOSPHATE; IN VIVO STUDY; LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SKELETAL MUSCLE; TRANSGENIC MOUSE; VIRAL GENE DELIVERY SYSTEM; WILD TYPE;

ANIMALS; BRAIN; CREATINE; CREATINE KINASE; ENERGY METABOLISM; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MUSCLE, SKELETAL; PHOSPHORUS COMPOUNDS; PHOSPHORYLATION;

MUS; MUS MUSCULUS;

EID: 34249687578     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1117     Document Type: Review

References (124)

1. Budinger TF, Benaron DA, Koretsky AP. Imaging transgenic animals. Annu. Rev. Biomed. Eng. 1999; 1: 611-648.
2. Ntziachristos V, Bremer C, Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur. Radiol. 2003; 13(1): 195-208.
3. MacLaren DC, Toyokuni T, Cherry SR, Barrio JR, Phelps ME, Herschman HR, Gambhir SS. PET imaging of transgene expression. Biol. Psychiatry 2000; 48(5): 337-348.
4. Brindle KM. NMR methods for measuring enzyme kinetics in vivo. Progress in NMR Spectroscopy 1988; 20: 257-293.
5. 31P magnetic resonance. J. Biol. Chem. 1973; 248(20): 7276-7278.
6. Pfeuffer J, Tkac I, Provencher SW, Gruetter R. Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time (1)H NMR spectra of the rat brain. J. Magn. Reson. 1999; 141(1): 104-120.
7. Renema WK, Schmidt A, Van Asten JJ, Oerlemans F, Ullrich K, Wieringa B, Isbrandt D, Heerschap A. MR spectroscopy of muscle and brain in guanidinoacetate methyltransferase (GAMT)-deficient mice: validation of an animal model to study creatine deficiency. Magn. Reson. Med. 2003; 50(5): 936-943.
8. 31P magnetic resonance study. J. Neurochem. 2004; 90(6): 1321-1330.
9. 13C nuclear magnetic resonance. FEBS Lett. 1982; 150(2): 489-493.
10. 13C NMR Studies of Cerebral Metabolism. John Wiley & Sons, Ltd: Chichester, UK, 2003; Vol. 16.
11. Heerschap A, Bergman AH, van Vaals JJ, Wirtz P, Loermans HM, Veerkamp JH. Alterations in relative phosphocreatine concentrations in preclinical mouse muscular dystrophy revealed by in vivo NMR. NMR Biomed. 1988; 1(1): 27-31.
12. Koretsky AP, Brosnan MJ, Chen L, Van Dyke T. NMR detection of creatine kinase expressed in liver of transgenic mice: determination of free ADP levels. Proc. Natl Acad. Sci. USA 1990; 87: 3112-3116.
13. van Deursen J, Heerschap A, Oerlemans F, Ruitenbeek W, Jap P, ter Laak H, Wieringa B. Skeletal muscles of mice deficient in muscle creatine kinase lack burst activity. Cell 1993; 74(4): 621-631.
14. Koretsky AP. Insights into cellular energy metabolism from transgenic mice. Physiol. Rev. 1995; 75(4): 667-688.
15. Dzeja PP, Terzic A. Phosphotransfer networks and cellular energetics. J. Exp. Biol. 2003; 206(Pt 12): 2039-2047.
16. Zeleznikar RJ, Dzeja PP, Goldberg ND. Adenylate kinase-catalyzed phosphoryl transfer couples ATP utilization with its generation by glycolysis in intact muscle. J. Biol. Chem. 1995; 270(13): 7311-7319.
17. Darling S. Mice as models of human developmental disorders: natural and artificial mutants. Curr. Opin. Genet. Dev. 1996; 6(3): 289-294.
18. Bulfield G, Siller WG, Wight PA, Moore KJ. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl Acad. Sci. USA 1984; 81(4): 1189-1192.
19. Kataoka S, Satoh J, Fujiya H, Toyota T, Suzuki R, Itoh K, Kumagai K. Immunologic aspects of the nonobese diabetic (NOD) mouse. Abnormalities of cellular immunity. Diabetes. 1983; 32(3): 247-253.
20. Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 1980; 29(1): 1-13.
21. Sarvetnick N, Liggitt D, Pitts SL, Hansen SE, Stewart TA. Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma. Cell 1988; 52(5): 773-782.
22. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84(3): 491-495.
23. Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower LA. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat. Genet. 1995; 9(3): 305-311.
24. http://web.ncifcrf.gov/researchresources/mmhcc/
25. Bock NA, Konyer NB, Henkelman RM, Multiple-mouse MRI. Magn. Reson. Med. 2003; 49(1): 158-167.
26. http://bio.lsd.ornl.gov/mgd/phenotype/
27. Searle AG, Edwards JH, Hall JG. Mouse homologues of human hereditary disease. J. Med. Genet. 1994; 31(1): 1-19.
28. Meisler MH. Insertional mutation of 'classical' and novel genes in transgenic mice. Trends Genet. 1992; 8(10): 341-344.
29. Shuldiner AR. Transgenic animals. N. Engl. J. Med. 1996; 334(10): 653-655.
30. Jaenisch R. Transgenic animals. Science 1988; 240(4858): 1468-1474.
31. Metzger D, Feil R. Engineering the mouse genome by site-specific recombination. Curr. Opin. Biotechnol. 1999; 10(5): 470-476.
32. Tsien JZ, Chen DF, Gerber D, Tom C, Mercer EH, Anderson DJ, Mayford M, Kandel ER, Tonegawa S. Subregion- and cell type-restricted gene knockout in mouse brain. Cell 1996; 87(7): 1317-1326.
33. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002; 295(5556): 868-872.
34. Pascoe WS, Kemler R, Wood SA. Genes and functions: trapping and targeting in embryonic stem cells. Biochim. Biophys. Acta 1992; 1114(2-3): 209-221.
35. Misra RP, Duncan SA. Gene targeting in the mouse: advances in introduction of transgenes into the genome by homologous recombination. Endocrine 2002; 19(3): 229-238.
36. Travis J. Scoring a technical knockout in mice. Science 1992; 256(5062): 1392-1394.
37. Charreau B, Tesson L, Soulillou JP, Pourcel C, Anegon I. Transgenesis in rats: technical aspects and models. Transgenic Res. 1996; 5(4): 223-234.
38. Capecchi MR. How close are we to implementing gene targeting in animals other than the mouse? Proc. Natl Acad. Sci. USA 2000; 97(3): 956-957.
39. Heerschap A, Sommers MG, in't Zandt HJ, Renema WK, Veltien AA, Klomp DW. Nuclear magnetic resonance in laboratory animals. Methods Enzymol. 2004; 385: 41-63.
40. 1H NMR spectra with increased magnetic field strength. J. Magn. Reson. 1998; 135(1): 260-264.
41. 1H NMR spectroscopy of the mouse brain at 9.4 T. Magn. Reson. Med. 2004; 52(3): 478-484.
42. Gadian DG. NMR and its application to living systems. Clarendon Press: Oxford, 1982.
43. de Graaf RA. In Vivo NMR Spectroscopy. Principles and Techniques, John Wiley & Sons, Ltd: Chichester, UK, 1998.
44. Giannesini B, Cozzone PJ, Bendahan D. In vivo MR investigation of skeletal muscle function in small animals. Magma 2004; 17(3-6): 210-218.
45. Choi IY, Lee SP, Guilfoyle DN, Helpern JA. In vivo NMR studies of neurodegenerative diseases in transgenic and rodent models. Neurochem. Res. 2003; 28(7): 987-1001.
46. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol. Rev. 2000; 80(3): 1107-1213.
47. Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the phosphocreatine circuit for cellular energy homeostatis. Biochem. J. 1992; 281: 21-40.
48. Wyss M, Smeitink J, Wevers RA, Wallimann T. Mitochondrial creatine kinase: a key enzyme of aerobic energy metabolism. Biochim. Biophys. Acta 1992; 1102(2): 119-166.
49. Wallimann T. Bioenergetics. Dissecting the role of creatine kinase. Curr. Biol. 1994; 4(1): 42-46.
50. Bessman SP, Fonyo A. The possible role of the mitochondrial bound creatine kinase in regulation of mitochondrial respiration. Biochem. Biophys. Res. Commun. 1966; 22(5): 597-602.
51. Bessman SP, Geiger PJ. Transport of energy in muscle: the phosphorylcreatine shuttle. Science 1981; 211(4481): 448-452.
52. Meyer RA, Sweeney HL, Kushmerick MJ. A simple analysis of the 'phosphocreatine shuttle'. Am. J. Physiol. 1984; 246(5 Pt 1). C365-C377.
53. in't Zandt HJ, Groof AJ, Renema WK, Oerlemans FT, Klomp DW, Wieringa B, Heerschap A. Presence of (phospho)creatine in developing and adult skeletal muscle of mice without mitochondrial and cytosolic muscle creatine kinase isoforms. J. Physiol. 2003; 548(Pt 3): 847-858.
54. Tachikawa M, Fukaya M, Terasaki T, Ohtsuki S, Watanabe M. Distinct cellular expressions of creatine synthetic enzyme GAMT and creatine kinases uCK-Mi and CK-B suggest a novel neuronglial relationship for brain energy homeostasis. Eur. J. Neurosci. 2004; 20(1): 144-160.
55. Tanabe T, Yamada M, Noma T, Kajii T, Nakazawa A. Tissue-specific and developmentally regulated expression of the genes encoding adenylate kinase isozymes. J. Biochem. (Tokyo) 1993; 113: 200-207.
56. Collavin L, Lazarevic D, Utrera R, Marzinotto S, Monte M, Schneider C. wt p53 dependent expression of a membrane-associated isoform of adenylate kinase. Oncogene 1999; 18(43): 5879-5888.
57. Van Rompay AR, Johansson M, Karlsson A. Identification of a novel human adenylate kinase. cDNA cloning, expression analysis, chromosome localization and characterization of the recombinant protein. Eur J. Biochem. 1999; 261(2): 509-517.
58. Yoneda T, Sato M, Maeda M, Takagi H. Identification of a novel adenylate kinase system in the brain: cloning of the fourth adenylate kinase. Brain Res. Mol. Brain Res. 1998; 62(2): 187-195.
59. Steeghs K, Heerschap A, de Haan A, Ruitenbeek W, Oerlemans F, van Deursen J, Perryman B, Pette D, Brueckwilder M, Koudijs J, Jap P, Wieringa B. Use of gene targeting for compromising energy homeostasis in neuro-muscular tissues: the role of sarcomeric mitochondrial creatine kinase. J. Neurosci. Methods 1997; 71: 29-41.
60. 2+ responses in muscles with combined mitochondrial and cytosolic creatine kinase deficiencies. Cell 1997; 89(1): 93-103.
61. van Deursen J, Ruitenbeek W, Heerschap A, Jap P, ter Laak H, Wieringa B. Creatine kinase (CK) in skeletal muscle energy metabolism: a study of mouse mutants with graded reduction in muscle CK expression. Proc. Natl Acad. Sci. USA 1994; 91(19): 9091-9095.
62. Jost CR, Van Der Zee CE, In't Zandt HJ, Oerlemans F, Verheij M, Streijger F, Fransen J, Heerschap A, Cools AR, Wieringa B. Creatine kinase B-driven energy transfer in the brain is important for habituation and spatial learning behaviour, mossy fibre field size and determination of seizure susceptibility. Eur. J. Neurosci. 2002; 15(10): 1692-1706.
63. Kekelidze T, Khait I, Togliatti A, Benzecry JM, Wieringa B, Holtzman D. Altered brain phosphocreatine and ATP regulation when mitochondrial creatine kinase is absent. J. Neurosci. Res. 2001; 66(5): 866-872.
64. van Deursen J, Jap P, Heerschap A, ter Laak H, Ruitenbeek W, Wieringa B. Effects of the creatine analogue beta-guanidinopropionic acid on skeletal muscles of mice deficient in muscle creatine kinase. Biochim. Biophys. Acta 1994; 1185(3): 327-335.
65. Boehm EA, Radda GK, Tomlin H, Clark JF. The utilisation of creatine and its analogues by cytosolic and mitochondrial creatine kinase. Biochim. Biophys. Acta 1996; 1274(3): 119-128.
66. Clark JF, Khuchua Z, Kuznetsov AV, Vassil'eva E, Boehm E, Radda GK, Saks V. Actions of the creatine analogue beta-guanidinopropionic acid on rat heart mitochondria. Biochem. J. 1994; 300 (Pt 1): 211-216.
67. 31P nuclear magnetic resonance spectroscopy. NMR Biomed. 1999; 12(6): 327-334.
68. 31P NMR using surface coils. Nature 1980; 283(5743): 167-170.
69. Meyer RA, Brown TR, Kushmerick MI. Phosphorus nuclear magnetic resonance of fast- and slow-twitch muscle. Am. J. Physiol. 1985; 248: C279-C287.
70. Brault JJ, Abraham KA, Terjung RL. Phosphocreatine content of freeze-clamped muscle: influence of creatine kinase inhibition. J. Appl. Physiol. 2003; 94(5): 1751-1756.
71. Roman BB, Meyer RA, Wiseman RW. Phosphocreatine kinetics at the onset of contractions in skeletal muscle of MM creatine kinase knockout mice. Am. J. Physiol. Cell Physiol. 2002; 283(6): C1776-C1783.
72. van Dorsten FA, Reese T, Gellerich JF, van Echteld CJ, Nederhoff MG, Muller HJ, van Vliet G, Nicolay K. Fluxes through cytosolic and mitochondrial creatine kinase, measured by P-31 NMR. Mol. Cell Biochem. 1997; 174(1-2): 33-42.
73. Nicolay K, van Dorsten FA, Reese T, Kruiskamp MJ, Gellerich JF, van Echteld CJ. In situ measurements of creatine kinase flux by NMR. The lessons from bioengineered mice. Mol. Cell Biochem. 1998; 184(1-2): 195-208.
74. in't Zandt HJA, Klomp DWJ, Oerlemans F, Wieringa B, Hilbers CW, Heerschap A. Proton MR spectroscopy of wild-type and creatine kinase deficient mouse skeletal muscle: dipole-dipole coupling effects and post-mortem changes. MRM 2000; 43: 517-524.
75. Kruiskamp MJ, van Vliet G, Nicolay K. 1H and (31)P magnetization transfer studies of hindleg muscle in wild-type and creatine kinase-deficient mice. Magn. Reson. Med. 2000; 43(5): 657-664.
76. Brosnan MJ, Raman SP, Chen L, Koretsky AP. Altering creatine kinase isoenzymes in transgenic mouse muscle by overexpression of the B subunit. Am. J. Physiol. 1993; 264(1 Pt 1): C151-C160.
77. Roman BB, Wieringa B, Koretsky AP. Functional equivalence of creatine kinase isoforms in mouse skeletal muscle. J. Biol. Chem. 1997; 272(28): 17790-17794.
78. Brosnan MJ, Halow JM, Koretsky AP. Manipulating creatine kinase activity in transgenic mice to study control of energy metabolism. Biochem. Soc. Trans. 1991; 19(4): 1010-1014.
79. Roman BB, Foley JM, Meyer RA, Koretsky AP. Contractile and metabolic effects of increased creatine kinase activity in mouse skeletal muscle. Am. J. Physiol. 1996; 270(4 Pt 1): C1236-C1245.
80. Streijger F, Oerlemans F, Ellenbroek BA, Jost CR, Wieringa B, Van der Zee CE. Structural and behavioural consequences of double deficiency for creatine kinases BCK and UbCKmit. Behav. Brain Res. 2005; 157(2): 219-234.
81. Kasischke KA, Vishwasrao HD, Fisher PJ, Zipfel WR, Webb WW. Neural activity triggers neuronal oxidative metabolism followed by astrocytic glycolysis. Science 2004; 305(5680): 99-103.
82. Pellerin L, Magistretti PJ. Neuroscience. Let there be (NADH) light. Science 2004; 305(5680): 50-52.
83. Streijger F, Jost CR, Oerlemans F, Ellenbroek BA, Cools AR, Wieringa B, Van der Zee CE. Mice lacking the UbCKmit isoform of creatine kinase reveal slower spatial learning acquisition, diminished exploration and habituation, and reduced acoustic startle reflex responses. Mol. Cell Biochem. 2004; 256-257(1-2): 305-318.
84. Veksler VI, Kuznetsov AV, Anflous K, Mateo P, van Deursen J, Wieringa B, Ventura-Clapier R. Muscle creatine kinase-deficient mice. II. Cardiac and skeletal muscles exhibit tissue-specific adaptation of the mitochondrial function. J. Biol. Chem. 1995; 270(34): 19921-19929.
85. Saupe KW, Spindler M, Tian R, Ingwall JS. Impaired cardiac energetics in mice lacking muscle-specific isoenzymes of creatine kinase. Circ. Res. 1998; 82(8): 898-907.
86. 31P NMR studies of creatine kinase flux in M-creatine kinase-deficient mouse heart. Am. J. Physiol. 1998; 275(4 Pt 2): H1191-H1199.
87. Spindler M, Niebler R, Renikes H, Horn M, Lanz T, Neubauer S. Mitochondrial creatine kinase is critically necessary for normal myocardial high-energy phosphate metabolism. Am. J. Physiol. Heart Circ. Physiol. 2002; 283(2): H680-H687.
88. Spindler M, Engelhardt S, Niebler R, Wagner H, Hein L, Lohse MJ, Neubauer S. Alterations in the myocardial creatine kinase system precede the development of contractile dysfunction in beta(1)-adrenergic receptor transgenic mice. J. Mol. Cell Cardiol. 2003; 35(4): 389-397.
89. Ingwall JS. Creatine kinase knockout mice - what is the phenotype: heart. Magma 1998; 6(2-3): 120-121.
90. Veech RL, Lawson JW, Cornell NW, Krebs HA. Cytosolic phosphorylation potential. J. Biol. Chem. 1979; 254(14): 6538-6547.
91. 31P nuclear magnetic resonance spectroscopy employing creatine kinase as a marker gene. Proc. Natl Acad. Sci. USA 2001; 98(9): 5205-5210.
92. Brosnan MJ, Chen L, Van Dyke TA, Koretsky AP. Free ADP levels in transgenic mouse liver expressing creatine kinase. Effects of enzyme activity, phosphagen type, and substrate concentration. J. Biol. Chem. 1990; 265(34): 20849-20855.
93. Miller K, Halow J, Koretsky AP. Phosphocreatine protects transgenic mouse liver expressing creatine kinase from hypoxia and ischemia. Am. J. Physiol. 1993; 265: C1544-C1551.
94. 31P-n.m.r. study of transgenic mice expressing creatine kinase (CKBB) in the liver. Biochem. J. 1994; 303(Pt 2): 531-538.
95. Brosnan MJ, Chen LH, Wheeler CE, Van Dyke TA, Koretsky AP. Phosphocreatine protects ATP from a fructose load in transgenic mouse liver expressing creatine kinase. Am. J. Physiol. 1991; 260(6 Pt 1): C1191-C1200.
96. Miller K, Sharer K, Suhan J, Koretsky AP. Expression of functional mitochondrial creatine kinase in liver of transgenic mice. Am. J. Physiol. 1997; 272: C1193-C1202.
97. Askenasy N, Koretsky AP. Transgenic livers expressing mitochondrial and cytosolic CK: mitochondrial CK modulates free ADP levels. Am. J. Physiol. Cell Physiol. 2002; 282(2): C338-C346.
98. Speer O, Back N, Buerklen T, Brdiczka D, Koretsky A, Wallimann T, Eriksson O. Octameric mitochondrial creatine kinase induces and stabilizes contact sites between the inner and outer membrane. Biochem. J. 2005; 385(Pt 2): 445-450.
99. Janssen E, Dzeja PP, Oerlemans F, Simonetti AW, Heerschap A, de Haan A, Rush PS, Terjung RR, Wieringa B, Terzic A. Adenylate kinase 1 gene deletion disrupts muscle energetic economy despite metabolic rearrangement. EMBO J. 2000; 19(23): 6371-6381.
100. 31P-NMR observation of free ADP during fatiguing, repetitive contractions of murine skeletal muscle lacking AK1. Am. J. Physiol. Cell Physiol. 2005; 288: C1298-C1304.
101. Janssen E, Terzic A, Wieringa B, Dzeja PP. Impaired intracellular energetic communication in muscles from creatine kinase and adenylate kinase (M-CK/AK1) double knock-out mice. J. Biol. Chem. 2003; 278(33): 30441-30449.
102. 31P MRS reveals a compromised phosphoryl transfer system in mice lacking both cytosolic CK and AK. Proc. Intl Soc. Magn. Reson. Med. 2002; 10: 1869.
103. Schmidt A, Marescau B, Boehm EA, Renema WK, Peco R, Das A, Steinfeld R, Chan S, Wallis J, Davidoff M, Ullrich K, Waldschutz R, Heerschap A, De Deyn PP, Neubauer S, Isbrandt D. Severely altered guanidino compound levels, disturbed body weight homeostasis and impaired fertility in a mouse model of guanidinoacetate N-methyltransferase (GAMT) deficiency. Hum. Mol. Genet. 2004; 13(9): 905-921.
104. Stöckler S, Holzbach U, Hanefeld F, Marquardt I, Helms G, Requart M, Hanicke W, Frahm J. Creatine deficiency in the brain: a new, treatable inborn error of metabolism. Pediatr. Res. 1994; 36(3): 409-413.
105. Kan HE, Renema WK, Isbrandt D, Heerschap A. Phosphorylated guanidinoacetate partly compensates for the lack of phosphocreatine in skeletal muscle of mice lacking guanidinoacetate methyltransferase. J. Physiol. 2004; 560(Pt 1): 219-229.
106. von Figura K, Hanefeld F, Isbrandt D, Stöckler-Ipsiroglu S. Guanidinoacetate methyltransferase deficiency. In: The Metabolic and Molecular Bases of Inherited Disease, Scriver CR, Beaudet AL, Sly WS, Valle D, Childs V (eds). McGraw-Hill: New York. 2001; Ch. 84.
107. 1H-MRS in the mouse. Magn. Reson. Med. 2004; 52(5): 1029-1035.
108. ten Hove M, Lygate CA, Fischer A, Schneider JE, Sang AE, Hulbert K, Sebag-Montefiore L, Watkins H, Clarke K, Isbrandt D, Wallis J, Neubauer S. Reduced inotropic reserve and increased susceptibility to cardiac ischemia/reperfusion injury in phosphocreatine-deficient guanidinoacetate-N-methyltransferase-knockout mice. Circulation 2005; 111(19): 2477-2485.
109. Walter G, Barton ER, Sweeney HL. Noninvasive measurement of gene expression in skeletal muscle. Proc. Natl Acad. Sci. USA 2000; 97(10): 5151-5155.
110. Li Z, Qiao H, Lebherz C, Choi SR, Zhou X, Gao G, Kung HF, Rader DJ, Wilson JM, Glickson JD, Zhou R. Creatine kinase, a magnetic resonance-detectable marker gene for quantification of liver-directed gene transfer. Hum. Gene Ther. 2005; 16(12): 1429-1438.
111. Wu C, Okar DA, Newgard CB, Lange AJ. Overexpression of 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase in mouse liver lowers blood glucose by suppressing hepatic glucose production. J. Clin. Invest. 2001; 107(1): 91-98.
112. 13C NMR measurements of hepatic carbohydrate metabolism. Eur. J. Biochem. 2002; 269(18): 4418-4426.
113. Schwarcz A, Natt O, Watanabe T, Boretius S, Frahm J, Michaelis T. Localized proton MRS of cerebral metabolite profiles in different mouse strains. Magn. Reson. Med. 2003; 49(5): 822-827.
114. Auerbach W, Hurlbert MS, Hilditch-Maguire P, Wadghiri YZ, Wheeler VC, Cohen SI, Joyner AL, MacDonald ME, Turnbull DH. The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. Hum. Mol. Genet. 2001; 10(22): 2515-2523.
115. Steeghs K, Oerlemans F, de Haan A, Heerschap A, Verdoodt L, de Bie M, Ruitenbeek W, Benders A, Jost C, van Deursen J, Tullson P, Terjung R, Jap P, Jacob W, Pette D, Wieringa B. Cytoarchitectural and metabolic adaptations in muscles with mitochondrial and cytosolic creatine kinase deficiencies. Mol. Cell Biochem. 1998; 184(1-2): 183-194.
116. ter Veld F, Jeneson JA, Nicolay K. Mitochondrial affinity for ADP is twofold lower in creatine kinase knock-out muscles. Possible role in rescuing cellular energy homeostasis. FEBS J. 2005; 272(4): 956-965.
117. Bailey JE. Lessons from metabolic engineering for functional genomics and drug discovery. Nat. Biotechnol. 1999; 17(7): 616-618.
118. 31P NMR studies using creatine analogs. J. Biol. Chem. 1995; 270(21): 12428-12438.
119. Hancock CR, Janssen E, Terjung RL. Skeletal muscle contractile performance and ADP accumulation in adenylate kinase deficient mice. Am. J. Physiol. Cell Physiol. 2005; 288(6): C1287-97.
120. Sjogaard G, Saltin B. Extra- and intracellular water spaces in muscles of man at rest and with dynamic exercise. Am. J. Physiol. 1982; 243(3): R271-R280.
121. Forsberg AM, Nilsson E, Werneman J, Bergstrom J, Hultman E. Muscle composition in relation to age and sex. Clin. Sci. (Lond.) 1991; 81(2): 249-256.
122. Mendez J, Keys A. Density and composition of mammalian muscle. Metabolism 1960; 9(184-188).
123. Torack RM, Alcala H, Gado M, Burton R. Correlative assay of computerized cranial tomography CCT, water content and specific gravity in normal and pathological postmortem brain. J. Neuropathol. Exp. Neurol. 1976; 35(4): 385-392.
124. Renema WKJ. Magnetic resonance spectroscopy of creatine-related energy metabolism in skeletal muscle and brain. PhD thesis: 2005; 213 pp.